Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Semaglutide, originally developed as a medication for managing type 2 diabetes, has gained attention for its remarkable efficacy in promoting weight loss
In a 1-year trial, patients who were administered lorcaserin lost an average of 5% of their body weight, while those in the placebo group only lost an average of 2% Medication update: The FDA has withdrawn lorcaserin, a medication used to treat obesity, due to concerns about its potential side effects
(8.1) Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation
Dosing is based on your response, not a generic schedule
In a November 4, 2024, press release, the company highlighted preliminary DIO model data: "[P]eripherally-restricted nimacimab achieve[d] significant dose-dependent weight loss" and "[p]reliminary data shows that nimacimab achieves desired metabolic outcomes." Three days later, CEO Dhillon reinforced this on an earnings call: "We believe nimacimabs first-in-class profile as a perfectly targeting CB1 inhibitor offers the right combination of efficacy and safety." The Q3 2024 10-Q echoed the theme, touting nimacimab's potential to "positively impact metabolic disorders including obesity." This optimism escalated
